News

News

OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL

First clinical trial to evaluate the safety and efficacy of OBI-3424, a DNA alkylating agent targeting AKR1C3 enzyme, in T-Cell Acute Lymphocytic Leukemia (T-ALL) and …

News

Poster Presentation at AACR 2021 Annual Meeting for OBI-3424, OBI-998, GLOBO H and SSEA-4

Title: Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424 Poster Number: 1220 / Abstract number: 1062 Title: Preclinical characterization of a novel SSEA4-targeting antibody …

News

OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4

Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule pro-drug), OBI-998 (SSEA-4 ADC) and the glycosphingolipid cancer antigens, Globo H and SSEA-4. …

News

OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference

Taipei, Taiwan. January 6, 2021 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Tillman Pearce, MD., Chief Medical Officer, will present …

News

ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

1. Presentation number: 397P / Poster: ID 680 Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients Presenter: Ching-Liang …